Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Reader Login
Indian Journal of Medical and Paediatric Oncology
Search Article 
  
Advanced search 
 
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   2005| March  | Volume 26 | Issue 1  
    Online since May 30, 2009

 
 
  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
 
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
Squamous cell carcinoma of face with xeroderma pigmentosa : a case report
S Pathy, KK Naik, S Bhaskar, MC Sharma, PK Julka, GK Rath
March 2005, 26(1):47-49
Xeroderma pigmentosa with squamous cell carcinoma of skin has been infrequently reported. A nine year old boy having xeroderma pigmentosa presented with extensive ulceration in the face. On investigations, the ulceration was found to be squamous cell carcinoma. The details of this case are presented and management with a short course of palliative radiotherapy is discussed.
[ABSTRACT]   Full text not available  [PDF]
  764 160 -
Recent advances in management of intravascular catheter related infections
AK Singhal, S Mishra, S Bhatnagar
March 2005, 26(1):31-40
Intravascular catheter-related infections are a major cause of morbidity and mortality. Coagulase-negative staphylococci, Staphylococcus aureus, aerobic gram-negative bacilli and Candida albicans are the commonest microorganisms implicated in catheter-related infections. Management of catheter-related infections varies according to type of catheter involved. After appropriate cultures of blood and catheter samples are done, empirical intravenous antimicrobial therapy should be initiated on the basis of clinical picture, severity of the acute illness, underlying disease and the potential pathogens involved. When a catheter related infection is documented and a specific pathogen is identified, systemic antimicrobial therapy should be narrowed and consideration given for antibiotic lock therapy, if the central venous catheter or implantable device is not removed. In all cases of catheter-related bacteremia and fungemia, the catheter should be removed, if the infection is complicated with septic thrombosis, endocarditis and osteomyelitis.
[ABSTRACT]   Full text not available  [PDF]
  681 151 -
Acute myeloid leukemia presenting with an unusual phenotype
S Ghosh, GK Shiva, S Shinde, Y Badrinath, S Dhond, H Jain, P Aamre
March 2005, 26(1):53-57
The diagnosis of acute myeloid leukemia (AML) requires expression of myeloid markers, CD13 and 33, positivity for myeloperoxidase and/or anti-MPO. AML with an unusual phenotype represented by myeloperoxidase positivity and absence of myeloid antigen expression is seen in less than 10 percent of cases. Myeloid antigens may be detected in the cytoplasm where they may be present before they are expressed on the cell surface. Here we present two rare cases of AML where the blasts were positive for myeloperoxidase and anti-MPO but negative for surface CD13 and CD33. Although AML-M2 with t (8; 21) is the subtype usually seen in these cases, one of our patients had biphenotypic leukemia with del power 9.
[ABSTRACT]   Full text not available  [PDF]
  689 135 -
Aggressive sinonasal hemangiopericytoma presenting with liver metastasis : a case report
R Pandey, A Patel, K Patel, S Shah, MJ Shan
March 2005, 26(1):50-52
Hemangiopericytoma is an uncommon soft tissue sarcoma. The tumour represents 2-3 percent of all soft tissue sarcomas in humans. This sarcoma arises from Zimmerman's pericytes. Sinonasal type hemangiopericytoma is an uncommon tumour of the upper aerodigestive tract. The majority of sinonasal hemangiopericytoma behave in a benign manner with excellent long term prognosis. Here we report an aggressive case of sinonasal hemangiopericytoma presenting with liver metastasis. This 42 year old male presented with epistaxis, a recurrent mass obstructing the lumen of the nose and a lump in right hypochondrium. His diagnosis after biopsy was interpreted as hemangiopericytoma. Ultrasonography showed multiple metastasis in the liver, which were also positive for metastatic sarcoma. This case highlights the fact that the usually benign sinonasal hemangiopericytoma can present with metastasis.
[ABSTRACT]   Full text not available  [PDF]
  665 157 -
Granulosa cell tumours of ovary : variables affecting prognosis
N Vimla, L Kumar, S Kumar, M Vijayaraghavan, N Bhatla, R Hariprasad
March 2005, 26(1):12-19
Background: Granulosa cell tumours account for less than 5 percent of all ovarian malignancies. Limited data is available from India. Methods: 27 patients with diagnosis of granulosa cell tumour of the ovary were treated between 1991 and 2003 at our Institute. The surgical records were reviewed and the patients were staged according to the FI6O system. The clinical and histological findings are correlated with prognosis and survival. Results: Mean age at diagnosis was 46.2 (2-64) years. The numberof patients in various stages was 1-19; II-l; III-5 and IV-2. Menstrual irregularity was diagnosed in 22 percent, and postmenopausal bleeding in 7.4 percent of women. Twenty-five patients were treated with primary surgery, 9 patients received adjuvant chemotherapy (CT) and only one patient received chemotherapy as primary treatment. Overall survival was 82 percent at 5 years. Overall survival for stage I was 100 percent after 5 and 10 years and in stage II-IV, was 56.4 percent after 5 and 10 years. Meantumour size was 18cm (range 3-30 cm). Women with larger tumour diameter (greater than 15cm) had significantly worse outcome than those with tumours of smaller diameter (P less than 0.05). The frequency of observed mitosis influenced the survival rate; with 0-3/10, HPF the survival was 100 percent in 5 years and with 4/10, HPF the survival was 2.6 years. Conclusion: The tumour size, mitotic rate and stage of disease are well-defined variables and influence the survival significantly and should be considered as important prognostic factors for treatment planning.
[ABSTRACT]   Full text not available  [PDF]
  681 128 -
Retrospective non-randomized comparative analysis of experience with two cisplatin based regimens in first line combination chemotherapy of advanced non-small cell lung cancer
K Lavrenkov, D Bobilev
March 2005, 26(1):5-11
Background: There is no single-standard treatment for locally advanced non-small cell lung cancer (NSCLC), but platinum based chemotherapy with one of the new generation agents is regarded as most effective for patients with good performance status. The purpose of this study is retrospective comparative analysis of response, toxicity and survival of two chemotherapy regimens containing cisplatin, combined with gemcitabine (GP) or vinorelbine (VP) in previously untreated patients with advanced NSCLC. Patient and Methods: Between 1998-2001, 60 patients (51 males and 9 females) with stage III B-IV NSCLC received chemotherapy. Fifty two patients (86.7 percent) presented with locally advanced (stage IIIB - 11 patients, 18.3 percent) or metastatic (stage IV - 41 patients, 68.4 percent), and 8 patients (13.3 percent) had metastases after previous radical surgery. The choice of chemotherapy regimen was a matter of distinction of treating physician. 31 patients received chemotherapy GP and 29 patients were treated with VP regimen. The groups were comparable in terms of age, performance state and stage of disease. Chemotherapy regimens consisted of either intravenous (i.v.) gemcitabine 1250 mg per m2 given over 30 minutes on days 1 and 8, and i.v. cisplatin 80 mg per m2 given over 2 hours on day 8, both repeated every 3 weeks, or i.v. vinorelbine 30 mg per m2 given over 10 minutes on days 1, 8 and 15 and i.v. cisplatin 80 mg per m2 given over 2 hours on day 1, both repeated every 4 weeks. Both regimens were planned to 6 cycles. Treatment was terminated in case of disease progression or unacceptable toxicity. All patients were evaluable for response and toxicity. Results: A total of 157 cycles of GP and 142 cycle of VP were given. Therapy was well-tolerated without any life threatening event. Grade III-IV toxicities for GP and VP regimens included vomiting in 0 percent vs 13.8 percent, neutropenia in 29 percent vs 68 percent (p=0.007), neutropenic fever 0 percent vs 10.3 percent, thrombocytopenia in 9.7 percent vs 0 percent, anemia in 3.2 percent vs 13.7 percent and peripheral neuropathy 0 percent vs 6.8 percent of patients respectively. Thirty one per cent of patients who received VP developed chemical phlebitis, that ultimated insertion of central venous access device. No complete responses (CR) were documented. Partial response (PR) was achieved in 29 percent of patients who received GP as compared with 20.7 percent of those treated with VP, the disease remained stable (SD) in 32.3 percent and 31 percent of patients respectively.. There was no statistically significant difference in survival between GP and VP groups. The median progression free survival was 7 months vs 4 months, the median survival was 12.5 vs 8.3 months and one-year survival was53 percent vs 45 percent respectively. Conclusions: To our experience, chemotherapy GP and VP for advanced NSCLC were both well tolerated. Though the rate of neutropenia was significantly higher in VP group, it was not life threatening. Response and survival analysis reveals no statistically significant difference between two regimens that correspond with data reported in the literature. Both GP and VP regimens may be used as a standard of care for advanced NSCLC.
[ABSTRACT]   Full text not available  [PDF]
  566 115 -
Wilms tumour with aniridia : a case report
N Choudhury, C Bhuyan, BJ Saikia, JD Sarma, PM Deka, N Bara
March 2005, 26(1):43-44
A 19 month old girl was diagnosed to have Wilms tumour. She was also detected to have bilateral aniridia. There were no other congenital anomalies. Her twin sister also has bilateral aniridia, but no evidence of Wilms tumour. The child was treated with neoadjuvant chemotherapy followed by surgery. She continues to be alive and disease-free at 30 months of follow up.
[ABSTRACT]   Full text not available  [PDF]
  561 103 -
Father and son with Hodgkin's disease : a case report
PSRK Sastry, A Sainani, C Bakshi, R Aggarwal, SH Advani
March 2005, 26(1):45-46
Full text not available  [PDF]
  383 128 -
Succesful management of tumour lysis syndrome in Burkitt's lymphoma
S Aggarwal, CS Kapoor, N Jain
March 2005, 26(1):58-59
Full text not available  [PDF]
  321 139 -
Chemotherapy for advance non-small cell lung cancer : quest for the best continues [editorial]
AK Pathak, V Kochupillai
March 2005, 26(1):3-4
Full text not available  [PDF]
  320 128 -
Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline mono chemotherapy : a multicenter study by the PETHEMA group
RS Patnaik
March 2005, 26(1):41-42
Full text not available  [PDF]
  330 92 -
  Feedback 
  Subscribe